Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Liabilities and Shareholders Equity (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Liabilities and Shareholders Equity data on record, last reported at $240.0 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 139.37% year-over-year to $240.0 million; the TTM value through Sep 2025 reached $539.0 million, up 14.12%, while the annual FY2024 figure was $119.2 million, 12.9% down from the prior year.
  • Liabilities and Shareholders Equity reached $240.0 million in Q3 2025 per ASMB's latest filing, up from $80.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $278.9 million in Q1 2021 and bottomed at $51.6 million in Q3 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $143.3 million, with a median of $119.9 million recorded in 2024.
  • Peak YoY movement for Liabilities and Shareholders Equity: tumbled 57.51% in 2023, then soared 139.37% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $191.1 million in 2021, then crashed by 46.72% to $101.8 million in 2022, then soared by 34.41% to $136.8 million in 2023, then decreased by 12.9% to $119.2 million in 2024, then skyrocketed by 101.39% to $240.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $240.0 million in Q3 2025, $80.8 million in Q2 2025, and $99.0 million in Q1 2025.